Cannabis
August 21, 2020 | |
Marc Ullman was quoted in a NutraIngredients USA article, “Upcoming event aims to help fill regulatory holes in hemp/CBD industry.”
The article discusses how CBD firms are often unprepared for the regulatory compliance side of operating a dietary supplement firm. The upcoming event that is being discussed in the article looks to assist with that.
Read MoreJuly 20, 2020 | | |
On August 27, Marc Ullman will be presenting at the American Herbal Products Association (AHPA) Hemp-CBD Supplement Virtual Congress. The seminar will provide companies with an understanding of federal and state legal and regulatory obligations and current issues and opportunities in the hemp-CBD market.
Click here to register.
Read MoreJune 15, 2020 | |
Marc Ullman was cited in Nutritional Outlook’s article, “High anxiety: Will CBD ever be legal in foods and beverages?”
The article discusses whether or not the FDA will ever approve the use of CBD in foods and beverages. Currently, it is not a lawful ingredient. Ullman provided advice on the procedures necessary to prove the
Read MoreJune 4, 2020 | |
Marc Ullman was quoted in a Nutraingredients-USA.com article entitled “Warning letter cites CBD’s regulatory status as leading issue.”
The Food and Drug Administration sent a warning letter to a supplement manufacturer regarding various failures in good manufacturing practice (GMP). For the first time, however, the letter cited the health claims made about CBD as the first
Read MoreJanuary 29, 2020 | |
On Thursday, January 30, 2020, Steven Shapiro will present to the New York State Bar Association’s Food, Drug and Cosmetic Law Section as part of its Off-Label Promotion Update. His presentation is entitled “Promotion of CBD following Epidiolex for Rx, OTC drugs and other products.
For information and to register, click here.
Read More| |
On January 29, 2020, Marc Ullman’s opinion piece, “FDA’s lack of CBD guidance is a disservice to Long Island firms,” appeared in Long Island Business News.
Marc notes that an exploding market for CBD products has created a conundrum for companies wishing to cash in. Either they obey FDA’s regulations and lose out, or they break
Read MoreJanuary 21, 2020 | |
Marc Ullman spoke to Nutraingredients-USA about a new bill that would include CBD in the definition of dietary supplements in the federal Food, Drug and Cosmetic Act. The legislation is an attempt to cope with the raft of products now on the market that are technically illegal.
Marc said he thinks the bill will only
Read MoreJanuary 17, 2020 | |
Marc Ullman was quoted in a Nutraingredients-USA story entitled “Warning letter analysis shows FDA has target on CBD, not hemp.”
To read the article, click here.
Read MoreDecember 5, 2019 | | |
Marc Ullman was quoted in a Natural Products Insider article, “CBD industry hit with nearly half a dozen class action lawsuits.” The FDA’s batch of warning letters last month to CBD marketers spawned a growing number of proposed class action lawsuits.
Click here to read the article.
Read MoreDecember 4, 2019 | |
Marc Ullman was quoted in a Nutraingredients-USA article, “Appeals court decision, recent warning letters open door for more CBD suits.”
Click here to read article.
Read More- AI
- Appeals
- Banking
- Bankruptcy
- Business Dissolution
- Cannabis
- Commercial Litigation
- Complex Torts & Product Liability
- Compliance Investigations & White Collar
- Construction
- Corporate
- Directors & Officers Liability
- Diversity & Inclusion
- Employment & Labor
- Environment
- General Liability
- Health Services
- Insurance Coverage
- Insurance Fraud
- Intellectual Property
- Medical Malpractice Defense
- Privacy, Data & Cyber Law
- Professional Liability
- Real Estate, Zoning & Land Use
- Tax
- Trusts & Estates